KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio-Rad Laboratories (BIO) EBT (2016 - 2025)

Historic EBT for Bio-Rad Laboratories (BIO) over the last 17 years, with Q4 2025 value amounting to $929.2 million.

  • Bio-Rad Laboratories' EBT rose 20223.35% to $929.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $995.5 million, marking a year-over-year increase of 14249.73%. This contributed to the annual value of $995.5 million for FY2025, which is 14249.73% up from last year.
  • As of Q4 2025, Bio-Rad Laboratories' EBT stood at $929.2 million, which was up 20223.35% from -$431.1 million recorded in Q3 2025.
  • Bio-Rad Laboratories' 5-year EBT high stood at $5.0 billion for Q3 2021, and its period low was -$4.4 billion during Q1 2022.
  • For the 5-year period, Bio-Rad Laboratories' EBT averaged around -$72.6 million, with its median value being $111.0 million (2023).
  • Per our database at Business Quant, Bio-Rad Laboratories' EBT plummeted by 43672.69% in 2022 and then surged by 52843.72% in 2024.
  • Over the past 5 years, Bio-Rad Laboratories' EBT (Quarter) stood at -$2.0 billion in 2021, then skyrocketed by 153.84% to $1.1 billion in 2022, then plummeted by 60.75% to $428.4 million in 2023, then tumbled by 312.16% to -$908.9 million in 2024, then surged by 202.23% to $929.2 million in 2025.
  • Its EBT was $929.2 million in Q4 2025, compared to -$431.1 million in Q3 2025 and $414.0 million in Q2 2025.